BioSpace News Archive

Aristea Therapeutics today announced the appointment of Ciara Kennedy as Aristea Therapeutics’ Chair of the Board of Directors and Fabio Magrini as Executive Medical Director.

Ascendis Pharma A/S (Nasdaq: ASND) today announced that the European Commission (EC) has granted marketing authorization for Lonapegsomatropin Ascendis Pharma (developed under the name TransCon hGH) as a once-weekly subcutaneous injection for the treatment of children and adolescents ages 3 to 18 years with growth failure due to insufficient secretion of endogenous growth hormone (also known as growth hormone deficiency, or GHD).

Accuredit Therapeutics announced a strategic partnership to establish a joint venture, Napoltec Life Sciences (Suzhou) Co., Ltd,

Biognosys, a leader in next-generation proteomics solutions for drug discovery and development, announced that it has obtained Good Laboratory Practice certification from Swiss health authorities for preclinical studies.

Edesa Biotech, Inc. today reported that the company has received approval from Health Canada to test its monoclonal antibody candidate, designated EB05, as a rescue therapy for critically ill patients in the Phase 3 part of a Phase 2/3 clinical study.

Assure Holdings Corp. announced that its remote neurology business, which launched in 2021, performed more than 2,100 remote neurology managed cases during the year.

NanoVibronix Inc today announced its board of directors has appointed Ms. Aurora (Rori) Cassirer and Ms. Maria (Lulu) Schroeder to serve as independent directors effective today.

Prellis Biologics, Inc. (Prellis), a Bay Area biotechnology company, announced today that it has entered into a multi-target drug discovery collaboration and licensing agreement with Bristol Myers Squibb.

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) is outlining major potential value drivers for 2022 at this morning’s presentation at the 40th Annual J.P. Morgan Healthcare Conference.

SynerFuse, Inc., a Minneapolis-based medical device company, is pleased to announce the first implantation in the company’s proof-of-concept study.